Company Updates Shareholders on CBD Initiative
CAVE CREEK, AZ–(Marketwired – Apr 20, 2016) – Endexx Corporation (OTC PINK: EDXC), a provider of innovative hemp derived phyto-nutrients and nutritional products, today announced the launch of a doctor supervised, adaptive clinical study to test the efficacy of its proprietary CBD capsule in response to patients suffering from neuropathic pain.
Dr. Martin Pressman, DPM in New Haven, Connecticut, Dr. Daniel Brandwein, DPM in Weston, Florida, Dr. Michael Horwitz, DPM and Dr. Daniel Kiddy, DPM, both in St Louis, Missouri will enroll twenty patients into four groups, for a one month study using CBD enriched capsules to evaluate neuropathic pain reduction.
The proprietary formulations are pharmacist formulated and manufactured capsules which include a dual pack as a day and night formula with cannabidiol as its primary active ingredient. Each patient will be taking two capsules a day with results to be monitored. At the end of the study, findings will be subjected to an independent peer review board.
This study is an extension of the work conducted by Dr. Kiddy with his patients and a follow up of Dr. Brandwein’s research that demonstrated an average pain reduction after 2 weeks of usage from 7 to 8 down to 3 to 4 on a pain scale of 1 to 10, using 4 to 5 drops of CBD-rich hemp oil twice a day.
Dr. Brandwein stated, “I am very excited about the upcoming new trial where we can follow the information even closer. I also believe that in a capsule form, patients will be more compliant and have better results. In some cases, my patients have decreased and discontinued their usage of Neurontin and Gabapentin.”
Todd Davis, CEO of Endexx provided an update to shareholders on its CBD initiative, and commented, “Endexx has defined two key market pathways for its CBD initiative: the consumer market for wellness and nutrition and the therapeutic and nutraceutical markets. Through the consumer market we are targeting the ‘Platinum’ age 40+ demographic seeking prolonged wellness, improved quality of life and the extension of an active lifestyle. Our phyto-cannabinoids-rich (PCR) products with Cannabidiol from Industrial Hemp have proven to significantly enhance overall wellness and improve physical and mental condition. On the therapeutic side, we have been formulating and testing CBD-infused products with certified compound pharmacists and physicians in a medical environment. Through this collaborative effort we have been able produce high-quality, safe and effective products and delivery formats. Physicians want to provide methods of treatment that support patient compliance and provide a clear beneficial solution for their patients.”
Endexx provides innovative medical marijuana management and technology solutions. Endexx, with its collaborative partners and consultants, develops and distributes consumable product lines derived from industrial hemp that is GMO and pesticides free and naturally rich in phytocannabinoids. The company has two technology products and services that launched in 2014 — the M3hub and the Autospense™. Both products provide essential solutions to promote regulatory compliance and full accountability through “seed to sale” inventory management and tracking. Based on principles developed by the pharmacological industry, the m3hub platform is the first standardized software solution for tracking pharmaceutical grade marijuana that maintains compliance with federal, state and local regulations. It is intended to provide a smooth transition to an eventual federal mandates. The Autospense™ is a high-tech marijuana inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailer, while enhancing their service quality by reducing transaction time for customers. Websites include: www.cbdunlimited.com, www.cbdhealthsolutions.com, www.endexx.com, www.m3hub.com.
Safe Harbor Notice
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
For further investor and media information, contact:
Chairman & CEO